NASDAQ:RTRX

Travere Therapeutics Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
$15.09
+0.49 (+3.36 %)
(As of 06/11/2021 12:00 AM ET)
Add
Compare
Today's Range
$14.43
$15.18
50-Day Range
$24.25
$28.18
52-Week Range
$8.98
$24.96
Volume1.05 million shs
Average Volume412,277 shs
Market Capitalization$770.37 million
P/E RatioN/A
Dividend YieldN/A
Beta0.67

Receive RTRX News and Ratings via Email

Sign-up to receive the latest news and ratings for Travere Therapeutics and its competitors with MarketBeat's FREE daily newsletter.


Travere Therapeutics logo

About Travere Therapeutics

Travere Therapeutics, Inc. is a biopharmaceutical company. It engages in the identification, development, commercialization, and distribution of therapies to people living with rare diseases. Its products include Chenodal, Cholbam, and Thiola. The company was founded by Martin Shkreli on February 8, 2008 and is headquartered in San Diego, CA.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

1.26 out of 5 stars

Medical Sector

904th out of 2,096 stocks

Pharmaceutical Preparations Industry

439th out of 830 stocks

Analyst Opinion: 3.4Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Travere Therapeutics (NASDAQ:RTRX) Frequently Asked Questions

Is Travere Therapeutics a buy right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Travere Therapeutics in the last twelve months. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Travere Therapeutics stock.
View analyst ratings for Travere Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Travere Therapeutics?

Wall Street analysts have given Travere Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Travere Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

How were Travere Therapeutics' earnings last quarter?

Travere Therapeutics, Inc. (NASDAQ:RTRX) posted its earnings results on Thursday, November, 5th. The biopharmaceutical company reported ($0.44) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.59) by $0.15. Travere Therapeutics had a negative trailing twelve-month return on equity of 36.38% and a negative net margin of 49.13%.
View Travere Therapeutics' earnings history
.

What price target have analysts set for RTRX?

5 brokers have issued 1 year price targets for Travere Therapeutics' shares. Their forecasts range from $21.00 to $33.00. On average, they anticipate Travere Therapeutics' stock price to reach $28.40 in the next twelve months. This suggests a possible upside of 88.2% from the stock's current price.
View analysts' price targets for Travere Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Travere Therapeutics' key executives?

Travere Therapeutics' management team includes the following people:
  • Eric Dube, President, Chief Executive Officer & Director
  • Laura M. Clague, Chief Financial & Accounting Officer
  • Bill Rote, Senior VP, Head-Research & Development
  • Noah L. Rosenberg, Chief Medical Officer
  • Elizabeth E. Reed, Secretary, Senior Vice President & General Counsel

Who are some of Travere Therapeutics' key competitors?

What other stocks do shareholders of Travere Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Travere Therapeutics investors own include CVS Health (CVS), Gilead Sciences (GILD), TG Therapeutics (TGTX), Dynavax Technologies (DVAX), Novavax (NVAX), Sangamo Therapeutics (SGMO), Heron Therapeutics (HRTX), Intercept Pharmaceuticals (ICPT), OPKO Health (OPK) and Exelixis (EXEL).

What is Travere Therapeutics' stock symbol?

Travere Therapeutics trades on the NASDAQ under the ticker symbol "RTRX."

What is Travere Therapeutics' stock price today?

One share of RTRX stock can currently be purchased for approximately $15.09.

How much money does Travere Therapeutics make?

Travere Therapeutics has a market capitalization of $770.37 million and generates $175.34 million in revenue each year. The biopharmaceutical company earns $-146,430,000.00 in net income (profit) each year or ($3.46) on an earnings per share basis.

How many employees does Travere Therapeutics have?

Travere Therapeutics employs 221 workers across the globe.

What is Travere Therapeutics' official website?

The official website for Travere Therapeutics is www.retrophin.com.

Where are Travere Therapeutics' headquarters?

Travere Therapeutics is headquartered at 3721 VALLEY CENTRE DR. SUITE 200, SAN DIEGO CA, 92130.

How can I contact Travere Therapeutics?

Travere Therapeutics' mailing address is 3721 VALLEY CENTRE DR. SUITE 200, SAN DIEGO CA, 92130. The biopharmaceutical company can be reached via phone at (888) 969-7879 or via email at [email protected]


This page was last updated on 6/12/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.